“Prestige Biopharma Sets Sights on Pancreatic Cancer Treatment Platform with New Diagnostic Device”

Prestige Biopharma (CEO Park So-yeon), which had no sales since listing in 2021, has secured a new cash cow.

The company’s position is to develop a ‘one-stop treatment platform for pancreatic cancer’, including early diagnosis, preventive vaccines, and treatments for pancreatic cancer, and the early diagnosis device is set to be commercialized in the second half of this year. In particular, if the supply of early diagnosis devices for pancreatic cancer is in full swing, it will become a new source of revenue for the company, which is expected to become another ‘cash cow’ soon.

Park So-yeon, CEO of Prestige Biopharma, said, “Pancreatic cancer is often in the late stage when it is discovered. Early detection is difficult and treatment is often missed. With the pancreatic cancer diagnosis kit, we will create a system that can quickly prevent and treat it.” We expect to be able to launch the product late this year or early next year at the earliest.”

photo-layout image photo_150720 max-width-600 float-center" data-idxno="150720" data-type="photo" style="display:inline-block">

◆ ‘PAUF’ gene target overexpressed in pancreatic cancer patients…’commercialization of diagnostic devices at the end of the year’

Currently, the company is focusing on conquering pancreatic cancer is ‘PAUF (Pancreatic Adenocarcinoma Up-regulated Factor)’. This is a protein factor that is overexpressed in more than 80% of pancreatic cancer patients, and antibody new drugs as well as diagnostic kits are targeting ‘PAUF’.

CEO Park said, “Because it is a secreted protein, we believed that it would travel through the bloodstream and developed a diagnostic method that can detect PAUF in the blood with very high sensitivity. “he said.

At the same time, the company was confident that clinical trials for pancreatic cancer treatment development and early pancreatic cancer diagnosis devices were going smoothly, and that the diagnostic kit would be commercialized by the end of this year at the earliest.

CEO Park said, “It is my hope that pancreatic cancer will be diagnosed before it progresses further by looking at the level of PAUF, and I am currently researching it. I think we will be able to release the product at the end of this year or early next year at the earliest.”

photo-layout image photo_150719 max-width-600 float-center" data-idxno="150719" data-type="photo" style="display:inline-block">

◆ ‘One-stop solution’ from pancreatic cancer diagnosis to preventive treatment

In addition, the company, which emphasizes that early diagnosis of pancreatic cancer is ‘an innovation for life that can increase the survival rate’, is also aiming for a ‘pancreatic cancer prevention vaccine’ targeting ‘PAUF’.

In particular, at the time of the Corona-19 pandemic in 2021, the company developed a vaccine for ‘Sputnik V’, a Russian vaccine, and has accumulated solid experience in producing ‘vaccine CDMO’. Accordingly, the company is also confident in the prevention vaccine for pancreatic cancer.

CEO Park said, “Early diagnosis through blood diagnosis of PAUF level, and PBP1510’s effect as a therapeutic agent that treats cancer and prolongs life by inhibiting PAUF. Then, if both of these are proved, it will be applied as a cancer vaccine. So, we plan to administer it for preventive purposes to those who show PAUF overexpression. So, I think these three are our own system that can conquer pancreatic cancer.”

Meanwhile, once the pancreatic cancer diagnostic kit clinical trial is completed, Prestige Biologics, a company specializing in CDMO, is expected to start full-scale clinical product and production, and Logics added antibody diagnostic device manufacturing to its business purpose in January.

photo-layout image photo_150724 max-width-600 float-center" data-idxno="150724" data-type="photo" style="display:inline-block">

◆ Commercialization of diagnostic devices to be visualized from the end of the year…’Expectation for a new cash cow’

In addition, the ‘pancreatic cancer diagnostic kit’ will serve as a new cash cow for the company, and we are confident of securing sales through commercialization as early as the end of this year.

CEO Park said, “We will accelerate the commercialization of PAUF diagnostic kits and release them at the end of this year or early next year. Securing sales through biosimilars and new antibody drugs is important, but in fact, if PAUF diagnostic kits are also commercialized, the diagnostic kit itself will become an important source of revenue.” can,” he said.

In addition, the company announced more full-scale research activities after the completion of IDC, and is expected to grow into a company that provides one-stop solutions ranging from the development of new drugs and biosimilars through preclinical and clinical development to product production CDMO.

Copyright © Pax Economy TV Unauthorized reproduction and redistribution prohibited